Skip to main content
SpringerLink
Log in
Book cover

Tumor Dormancy, Quiescence, and Senescence, Vol. 3 pp 51–57Cite as

Various Factors Contributing to Tumor Dormancy: Therapeutic Implications in Breast Cancer

  • Chapter
  • First Online:

  • 494 Accesses

Part of the book series: Tumor Dormancy and Cellular Quiescence and Senescence ((DOQU,volume 3))

Abstract

Cancer dormancy describes a stage in tumor progression where tumor cells survive in a quiescent state. Breast cancer is especially known for prolonged asymptomatic periods (up to 15–20 years) followed by a recurrence. Two main mechanisms of tumor cell dormancy are under discussion: tumor cells cease dividing completely or persist proliferating at a slow rate counterbalanced by apoptosis. In the last decades, major efforts have been made to understand the process of interaction between circulating tumor cells (CTCs) in the bloodstream and their extravasation into distant sites, where CTCs may survive in a dormant state or acquire the ability to build metastases. Despite remarkable progress in this field, factors that determinate the fate of a single tumor cell remain to be clarified.

An important hypothesis explaining the phenomenon of tumor cell dormancy is the stem cell theory. This theory indicates stem cell-like characteristics of at least a fraction of dormant CTCs that allows them to persist in the secondary sites and resist standard chemotherapies. Since dormant tumor cells are considered to cause relapse and metastases after long asymptomatic period, an understanding of their biology may be crucial for development of new therapeutic strategies to eradicate this distinct cell population and prevent recurrence. In this chapter we discuss biological mechanisms and clinical implications of tumor cell dormancy in breast cancer patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7(11):834–846

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Ashworth TR (1869) A case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust Med J 14:146–149

    Google Scholar 

  • Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12(19):5615–5621

    Article  PubMed  CAS  Google Scholar 

  • Banys M, Krawczyk N, Becker S, Jakubowska J, Staebler A, Wallwiener D, Fehm T, Rothmund R (2012) The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat 132(1):121–129

    Article  PubMed  Google Scholar 

  • Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoenorhoff MJ, Liu ZY, Costes SV, Cho EH, Lockett S, Khanna C, Chambers AF, Green JE (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68(15):6241–6250

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Becker S, Solomayer E, Becker-Pergola G, Wallwiener D, Fehm T (2007) Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat 106(2):239–243

    Article  PubMed  Google Scholar 

  • Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410

    Article  PubMed  CAS  Google Scholar 

  • Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V (2004) Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 10(24):8185–8194

    Article  PubMed  CAS  Google Scholar 

  • Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802

    Article  PubMed  CAS  Google Scholar 

  • Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC, Chambers AF, MacDonald IC (2000) Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 60(9):2541–2546

    PubMed  CAS  Google Scholar 

  • Clezardin P, Ebetino FH, Fournier PG (2005) Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65(12):4971–4974

    Article  PubMed  CAS  Google Scholar 

  • Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791

    Article  PubMed  CAS  Google Scholar 

  • Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G (1996) Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 41(2):177–185

    Article  PubMed  CAS  Google Scholar 

  • Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Durr-Storzer S, Neubauer H, Seeger H, Staebler A, Wallwiener D, Becker S (2008a) ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 10(5):R76

    Article  PubMed  Google Scholar 

  • Fehm T, Mueller V, Marches R, Klein G, Gueckel B, Neubauer H, Solomayer E, Becker S (2008b) Tumor cell dormancy: implications for the biology and treatment of breast cancer. APMIS 116(7–8):742–753

    Article  PubMed  CAS  Google Scholar 

  • Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124(4):619–626

    Article  PubMed  CAS  Google Scholar 

  • Holen I, Coleman RE (2010) Bisphosphonates as treatment of bone metastases. Curr Pharm Des 16(11):1262–1271

    Article  PubMed  CAS  Google Scholar 

  • Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Eaton CL (2005) Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo–a role in tumour cell survival? Breast Cancer Res Treat 92(3):207–215

    Article  PubMed  CAS  Google Scholar 

  • Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1(2):149–153

    Article  PubMed  CAS  Google Scholar 

  • Hussein O, Komarova SV (2011) Breast cancer at bone metastatic sites: recent discoveries and treatment targets. J Cell Commun Signal 5(2):85–99. doi:10.1007/s12079-011-0117-3

    Article  PubMed  PubMed Central  Google Scholar 

  • Indraccolo S, Stievano L, Minuzzo S, Tosello V, Esposito G, Piovan E, Zamarchi R, Chieco-Bianchi L, Amadori A (2006) Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc Natl Acad Sci U S A 103(11):4216–4221

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K (2005) The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103(5):884–891

    Article  PubMed  Google Scholar 

  • Karrison TG, Ferguson DJ, Meier P (1999) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91(1):80–85

    Article  PubMed  CAS  Google Scholar 

  • Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmuller G (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360(9334):683–689

    Article  PubMed  CAS  Google Scholar 

  • Krag DN, Ashikaga T, Moss TJ, Kusminsky RE, Feldman S, Carp NZ, Moffat FL, Beitsch PD, Frazier TG, Gaskin TA, Shook JW, Harlow SP, Weaver DL (1999) Breast cancer cells in the blood: a pilot study. Breast J 5(6):354–358

    Article  PubMed  Google Scholar 

  • Krawczyk N, Banys M, Neubauer H, Solomayer EF, Gall C, Hahn M, Becker S, Bachmann R, Wallwiener D, Fehm T (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res 29(10):4019–4024

    PubMed  Google Scholar 

  • Liotta LA, Kleinerman J, Saidel GM (1974) Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34(5):997–1004

    PubMed  CAS  Google Scholar 

  • Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153(3):865–873

    Article  PubMed  CAS  Google Scholar 

  • Mehes G, Witt A, Kubista E, Ambros PF (2001) Circulating breast cancer cells are frequently apoptotic. Am J Pathol 159(1):17–20

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW (2004a) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10(24):8152–8162

    Article  PubMed  Google Scholar 

  • Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J (2004b) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101(25):9393–9398

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, Vessella RL (2009) Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 15(2):677–683

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J, Almog N (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98(5):316–325

    Article  PubMed  Google Scholar 

  • Paget S (1889) Distribution of secondary growths in cancer of the breast. Lancet 1:571

    Article  Google Scholar 

  • Pawelec G, Heinzel S, Kiessling R, Muller L, Ouyang Q, Zeuthen J (2000) Escape mechanisms in tumor immunity: a year 2000 update. Crit Rev Oncog 11(2):97–133

    PubMed  CAS  Google Scholar 

  • Rack BK, Schindlbeck C, Andergassen U, Schneeweiss A, Zwingers T, Lichtenegger W, Beckmann M, Sommer HL, Pantel K, Janni W (2010) Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: the SUCCESS trial. ASCO annual meeting 2010. J Clin Oncol 28:15s (suppl; abstr 1003)

    Google Scholar 

  • Rack B, Juckstock J, Gunthner-Biller M, Andergassen U, Neugebauer J, Hepp P, Schoberth A, Mayr D, Zwingers T, Schindlbeck C, Friese K, Janni W (2012) Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Arch Gynecol Obstet 285(2):485–492

    Article  PubMed  CAS  Google Scholar 

  • Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O’Shaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252–1260

    Article  PubMed  CAS  Google Scholar 

  • Solomayer EF, Gebauer G, Hirnle P, Janni W, Luck HJ, Becker S, Huober J, Kramer B, Wackwitz B, Wallwiener D, Fehm T (2012) Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 23(9):2271–2277

    Article  PubMed  Google Scholar 

  • Townson JL, Chambers AF (2006) Dormancy of solitary metastatic cells. Cell Cycle 5(16):1744–1750

    Article  PubMed  CAS  Google Scholar 

  • Vitetta ES, Tucker TF, Racila E, Huang YW, Marches R, Lane N, Scheuermann RH, Street NE, Watanabe T, Uhr JW (1997) Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. Blood 89(12):4425–4436

    PubMed  CAS  Google Scholar 

  • Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massague J (2009) Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16(1):67–78

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. GYN/OB, Moorenstrasse 5, 40225, Dusseldorf, Germany

    Natalia Krawczyk, Malgorzata Banys, Hans Neubauer & Tanja Fehm

Authors
  1. Natalia Krawczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Malgorzata Banys
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans Neubauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tanja Fehm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Natalia Krawczyk .

Editor information

Editors and Affiliations

  1. Department of Biological Sciences, Kean University, Union, New Jersey, USA

    M.A. Hayat

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Krawczyk, N., Banys, M., Neubauer, H., Fehm, T. (2014). Various Factors Contributing to Tumor Dormancy: Therapeutic Implications in Breast Cancer. In: Hayat, M. (eds) Tumor Dormancy, Quiescence, and Senescence, Vol. 3. Tumor Dormancy and Cellular Quiescence and Senescence, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9325-4_5

Download citation

Publish with us

Policies and ethics

Search

Navigation